Alloy / M4 Body Treatment Rx
ESTRIOL 0.2% + PEPTIDES
The concentration is published here — estriol 0.2% — along with the full ingredient list and the study's sample size. All three are improvements on the face cream. But this one goes on chest, arms and legs, and the page says nothing at all about absorption, dose per application, or who should not use it.
There is a real reason to hesitate. Read the finding before you buy.
ASSESSED ON 75% OF THE MODEL. 2 CRITERIA LEFT UNSCORED — SEE SCORING FOR WHY.
Ask how much to apply and over how much skin. This is a hormone going onto chest, arms and legs, and the page gives no quantity of any kind.
The verdict
Three things here are better than the M4 face cream we reviewed alongside it. The estriol concentration is published — 0.2%, stated in the description and again inside the ingredient list. The full ingredient list is published, with the active's strength in it. And the study carries a sample size, a duration and named instruments: twelve weeks, n=38, measured with Corneometer, Moisturemeter EpiD, Cutometer and Antera 3D, plus expert visual and tactile grading. That is a real methodology, described in enough detail to argue with.
Then look at what the headline figures actually are. Ninety-seven per cent agree skin felt more hydrated. Ninety-five per cent felt smoother skin. Eighty-four per cent saw firmer skin. Seventy-nine per cent saw improvement in crepiness. Agree, felt, saw, saw. Alloy ran four instruments capable of measuring hydration, elasticity and surface topography objectively, named them in the footnote, and headlined the questionnaire. No instrumental result is reported anywhere, and unlike the face cream's study, no control arm is mentioned at all.
The more serious issue is where this goes. The face cream is applied to a face. This is indicated for 'the chest, legs, arms, hands or knees' — and the evidence that topical estriol produces no measurable change in circulating hormones comes from trials that applied it to faces. Concentration is not exposure. Exposure is concentration multiplied by area, frequency and duration, and moving from a face to a chest and two limbs changes one of those terms by more than an order of magnitude.
On the page that most needs to address this, there is nothing. The words bloodstream, systemic and absorption appear zero times. So do side effects, contra-indications, pregnancy and breast cancer. There is no application quantity — no pump count, no measure, no 'apply sparingly' — and no fill size, so the daily dose of a hormone cannot be worked out even in principle. The face cream at least made an absorption claim we could examine. This one is silent, and it is the product where silence costs more.
- Publishes the estriol concentration — 0.2% — in the description and again inside the ingredient list.
- Publishes the full ingredient list, which four compounding competitors decline to do.
- Discloses the study's sample size, n=38, and its twelve-week duration.
- Names the instruments used: Corneometer, Moisturemeter EpiD, Cutometer and Antera 3D.
- Names both peptides specifically rather than hiding behind 'peptide complex'.
- Palmitoyl pentapeptide-4 is a reasonable partner for an estrogen aimed at collagen.
- Fragrance-free and stated non-comedogenic, in a sensible emollient base.
- Treats a real and under-served problem — crepiness and laxity below the neck after menopause.
- Real prescription gating with a menopause-specialised physician reviewing medical history.
- $65 a month including unlimited doctor access, free delivery and HSA/FSA eligibility.
- Indicated for chest, legs, arms, hands and knees, while the no-systemic-effect evidence comes from facial application.
- Zero mentions of absorption, systemic effect or bloodstream anywhere on the page.
- Zero mentions of side effects, contra-indications, pregnancy or breast cancer.
- No application quantity of any kind — no pump count, no measure, no guidance on how much skin to cover.
- No fill size, so the daily dose of a hormone cannot be calculated even approximately.
- All four headline figures are self-reported, despite four objective instruments being run.
- No instrumental result is reported anywhere, and no control arm is mentioned.
- n=38 with no journal, authors or link.
- Acetyl hexapeptide-8 targets expression lines on body sites that do not have any.
- Compounded status unstated, as on the face cream, though estriol has no FDA-approved US form.
- The FAQ asks 'Do I need progesterone?' — the endometrial question that only arises with systemic estrogen — and the answer is not in the page's static content.
Every active, assessed
- Estriol0.2%
Weak estrogen — binds dermal estrogen receptors, stimulates fibroblast collagen and hyaluronic acid synthesis
- BENCHMARK
- 0.3% is the concentration used in the controlled facial trials
- ASSESSMENT
- Published, which is the single biggest improvement over the face cream, and slightly below the concentration the facial literature used. That sounds reassuring and is not the whole picture: a lower concentration spread over chest, arms and legs delivers considerably more hormone than a higher one on a face. The number a buyer needs is not the percentage but the milligrams per application and the area covered, and neither is given.
- Palmitoyl Pentapeptide-4NOT STATED
Signal peptide — matrix-stimulating, upregulates collagen and fibronectin
- BENCHMARK
- Typically used around 3 ppm to 8 ppm of the peptide itself
- ASSESSMENT
- A sensible companion to an estrogen aimed at collagen, and the better evidenced of the two peptides here. It sits near the end of the ingredient list, which places it below the preservatives, so it is present at the low levels this peptide is normally used at.
- Acetyl Hexapeptide-8NOT STATED
Neuropeptide marketed to reduce expression lines by interfering with neurotransmitter release at the neuromuscular junction
- BENCHMARK
- Facial expression lines are the only claimed indication
- ASSESSMENT
- Out of place. This peptide is sold on the premise of softening lines caused by repeated facial muscle contraction. Chests, arms, legs and knees do not have expression lines. Whatever it is contributing to a body treatment, it is not the thing it is known for, and its presence lets the page say 'estriol + peptides' with a plural.
| ACTIVE | CONC. | BENCHMARK | ASSESSMENT |
|---|---|---|---|
| EstriolWeak estrogen — binds dermal estrogen receptors, stimulates fibroblast collagen and hyaluronic acid synthesis | 0.2% | 0.3% is the concentration used in the controlled facial trials | Published, which is the single biggest improvement over the face cream, and slightly below the concentration the facial literature used. That sounds reassuring and is not the whole picture: a lower concentration spread over chest, arms and legs delivers considerably more hormone than a higher one on a face. The number a buyer needs is not the percentage but the milligrams per application and the area covered, and neither is given. |
| Palmitoyl Pentapeptide-4Signal peptide — matrix-stimulating, upregulates collagen and fibronectin | NOT STATED | Typically used around 3 ppm to 8 ppm of the peptide itself | A sensible companion to an estrogen aimed at collagen, and the better evidenced of the two peptides here. It sits near the end of the ingredient list, which places it below the preservatives, so it is present at the low levels this peptide is normally used at. |
| Acetyl Hexapeptide-8Neuropeptide marketed to reduce expression lines by interfering with neurotransmitter release at the neuromuscular junction | NOT STATED | Facial expression lines are the only claimed indication | Out of place. This peptide is sold on the premise of softening lines caused by repeated facial muscle contraction. Chests, arms, legs and knees do not have expression lines. Whatever it is contributing to a body treatment, it is not the thing it is known for, and its presence lets the page say 'estriol + peptides' with a plural. |
Scoring
- EVIDENCE FOR THE ACTIVEWEIGHT 30%66/100
Estriol has a genuine base for skin ageing and 0.2% is published and close to the trial range, with a study that discloses n=38, twelve weeks and four named instruments. Held back because no control arm is described, because every headline figure is self-reported despite those instruments being run, because n=38 is small and uncited to any journal, and because the efficacy evidence for estriol was generated on facial skin rather than the sites this product targets.
- FORMULATION INTEGRITYWEIGHT 20%68/100
The best composition disclosure of any compounded product in this register: a full ingredient list with the active's concentration printed inside it, in a competent fragrance-free base with squalane, glycerin and olive oil. Palmitoyl pentapeptide-4 is a defensible partner for an estrogen. Marked down for acetyl hexapeptide-8, which treats expression lines on skin that has none, and for giving no fill size and no application quantity for a prescription hormone.
- DISCLOSUREWEIGHT 15%34/100
Composition disclosure improves markedly on the face cream — concentration, full list, sample size, named instruments. Safety disclosure does not move at all: side effects, contra-indications, pregnancy and breast cancer are each mentioned zero times. And absorption disclosure goes backwards, because the face cream at least addressed it and this page, applied over vastly more skin, says nothing. No application quantity and no fill size for a hormone compounds it.
- TOLERANCE IN USEWEIGHT 15%NOT ASSESSED
Not assessed. A bland emollient base on body skin is unlikely to irritate, and the page offers no adverse-effect profile to check against in any case.
- TEXTURE & WEARWEIGHT 10%NOT ASSESSED
Not assessed. Requires the product in hand across the twelve-week window.
- COST PER APPLICATIONWEIGHT 10%52/100
$195 for a stated three-month supply is $65 a month, thirty per cent more than the face cream, with unlimited physician access, delivery and HSA/FSA eligibility included. Held back harder than the face cream because 'one bottle' covering chest, arms and legs for three months is a much weaker claim without a volume — the larger the area treated, the more a missing fill size matters, and it is missing.
What it is
A prescription topical estrogen for the body, built around estriol at 0.2% in a peptide-containing base, aimed at crepiness, dryness and loss of firmness below the neck after menopause. $195 for a stated three-month supply — $65 a month — including unlimited access to a menopause-specialised physician, free delivery and HSA/FSA eligibility.
It fixes the face cream's worst disclosure gap
Our main criticism of the M4 face cream was that it published a complete ingredient list and then withheld the one number that mattered — how much estriol. This page does not. The description states 'combining 0.2% estriol in a peptide-rich base', and the ingredient list opens with 'Estriol 0.2%'.
The study is better specified too. The face cream cited 'an independent clinical study' and nothing else. Here the footnote reads: a twelve-week clinical study, n=38, using Corneometer, Moisturemeter EpiD, Cutometer and Antera 3D instrumental measurements, expert visual and tactile grading, and a self-assessment questionnaire. That is a described methodology, and the instruments named are the standard ones for hydration, elasticity and surface topography.
Six things a buyer of a prescription hormone cream needs: the active's concentration, a full ingredient list, the study's sample size, whether there was a control arm, any safety content, and how much to apply. Between them the two pages supply three, and not the same three.
Four instruments were used. The questionnaire got the headlines.
A Corneometer measures stratum corneum hydration by capacitance. A Cutometer measures skin firmness and elasticity by suction. An Antera 3D images surface topography. These are the objective tools, and Alloy names all of them.
Here is what the page reports:
- 97% agree skin felt more hydrated.
- 95% felt smoother skin.
- 84% saw firmer skin.
- 79% saw improvement in crepiness.
Agree. Felt. Saw. Saw. Every headline figure is the self-assessment questionnaire. Not one instrumental result appears anywhere on the page — no hydration change, no elasticity change, no topography change, despite the instruments capable of producing all three being listed in the same footnote.
We have criticised Musely eight times for headline percentages that were uncontrolled day-30 self-report. The complaint there was that no better data existed. Here better data plainly does exist — it was collected, with named instruments, over twelve weeks — and the page prints the survey instead. A single Corneometer or Cutometer figure would have been the strongest efficacy claim in this register. And unlike the face cream, no control arm is mentioned at all, so even the survey numbers have nothing to be measured against.
The evidence is facial. The product is not.
The reassurance underpinning this whole product line — stated explicitly on the face cream page, and reasonable there — is that topical estriol does not change circulating hormone levels. That conclusion rests on controlled work in which estriol was applied to faces, with serum FSH, prolactin and estradiol measured monthly and found unchanged.
This product is for 'the chest, legs, arms, hands or knees'.
Body surface area by the standard rule-of-nines proportions used in burn assessment. Nobody applies to every named site at once, and the real figure will be lower — but the gap between the area the safety evidence covers and the area this product names is the point, and it is more than an order of magnitude at the top end.
Concentration is not exposure. Exposure is concentration multiplied by area, by frequency, by duration. At 0.2% this cream is slightly weaker than the 0.3% used in the facial trials, and that sounds like a margin of safety until you notice that the area term has changed by a factor of twelve or more. A weaker cream over twenty times the skin is not a smaller dose.
There is a further reason to want this addressed rather than assumed. Alloy sells estradiol gel, one menu away, as systemic menopausal hormone therapy — and estradiol gel works by being rubbed onto the arm or thigh. Transdermal application to body skin is not a theoretical route to the bloodstream; it is the established one, and this company uses it deliberately in another product.
Estriol is a genuinely weak estrogen — far less potent at the receptor than estradiol, and cleared quickly. A 0.2% estriol cream and a therapeutic estradiol gel are not the same proposition, and it is entirely possible that body application of this product produces no meaningful systemic exposure either. We are not asserting that it does. We are pointing out that the page does not say, that the evidence it leans on was generated somewhere else on the body, and that the one company positioned to answer the question has chosen not to raise it.
No dose, and no way to work one out
Searched across the page: no application quantity of any kind. No pump count, no measure, no fingertip unit, no instruction to use sparingly or to limit the area treated in one sitting. And no fill size — 'one bottle (3-month supply)' is the entire specification.
For a moisturiser that would be a minor omission. For a prescription hormone applied to large areas it means a buyer cannot compute their exposure even roughly, because both terms are missing: they do not know the volume in the bottle and they are not told how much to use. Obagi's hydroquinone label, written in 2010, manages 'a thin application... twice daily' and '2 oz (57 g)'. That is the bar, and it is a low one.
The safety section, again
This page has the same four tabs as the face cream, one of them headed Safety Information, and it contains the same thing: a product description, who it is for, what you get, and how to obtain a prescription.
Side effects: zero mentions. Contra-indications: zero. Pregnancy: zero. Breast cancer: zero. The pattern we identified on the face cream is confirmed rather than corrected, which moves it from an oversight on one page to a house convention across a product line.
One detail is worth noting because it suggests Alloy knows the question exists. The FAQ list includes 'Do I need progesterone?' — which is the endometrial protection question, and it only arises if estrogen is reaching the endometrium. Alloy has put that question on a skincare page. The answer is rendered by script and does not appear in the page's static content, so we cannot report what it says; that it is being asked at all is the point.
If you are considering it
- If you have any history of breast, endometrial or other hormone-sensitive cancer, or take tamoxifen or an aromatase inhibitor, raise it before ordering. The page will not.
- Ask how much to apply per session and over how much skin. That is the dose, and it is not on the page.
- Ask what the bottle contains in millilitres, and check it against the area you intend to treat for three months.
- Ask whether body-surface application changes the systemic picture compared with facial use. It is a fair question and a prescriber should have an answer.
- Ask for the instrumental results. The Corneometer and Cutometer data exist; the survey is what you have been shown.
- If you are already on hormone therapy, tell the prescriber — the interaction question is more live here than on a face cream.
- Treat the smallest area that bothers you first rather than everywhere at once.
- Give it twelve weeks, which is the study window and the page's own timeline.
Where we stand
At 58 this lands a point below the face cream, and the two scores hide a real trade. On composition this page is clearly better: the concentration is published, the ingredient list is complete, the sample size and the instruments are named. Those are exactly the disclosures we asked for in the previous review, and Alloy already makes them here.
On everything else it is the same page or a worse one. The safety section still contains no safety information. No one is told they should not use it. And on the single question this product raises more sharply than any other in the range — what happens when you put a hormone on a third of your skin every day for three months — the page is silent, where the face cream at least offered an answer we could examine.
Publish the instrumental results; they are the best argument this product has and they are being wasted. Give a quantity and a fill size, so exposure can be calculated. Say something, anything, about body-surface application and systemic estrogen. And put real safety information under the heading that promises it. The formulation work here is better than the register average; the paperwork is a long way behind it.
Who this is for
- A perimenopausal or menopausal woman with crepey, thinning skin below the neck, no history of hormone-sensitive cancer, and a prescriber who will discuss dose and area.
- Someone who wants the concentration published and will use it — 0.2% is real information the face cream withholds.
- Someone who will ask what a bottle contains and how much to apply, and treat the answer as part of the purchase.
- Someone who understands they are applying a hormone, not a moisturiser, and wants that supervised.
- You have a personal history of breast, endometrial or other hormone-sensitive cancer, or are taking tamoxifen or an aromatase inhibitor. Ask a specialist — this page says nothing at all.
- You would be treating large areas daily and want to know your total hormone exposure. Nothing here lets you calculate it.
- You are pregnant or breastfeeding. No position is offered and there should be one.
- You want the objective results from the instruments that were actually used.
- You want a defined volume so you can check that one bottle really covers chest, arms and legs for three months.
Ask how much to apply and over how much skin. This is a hormone going onto chest, arms and legs, and the page gives no quantity of any kind.
This is an editorial assessment of published information about a prescription product. It is not a diagnosis, not a prescription and not a substitute for your own prescriber. Hydroquinone and tretinoin are drugs. Decisions about them belong with a clinician who has seen your skin.
Sources
- S-01Alloy — M4 Body Treatment Rx product page The $195 three-month price, estriol 0.2% stated in the description and the ingredient list, the full ingredient list including both peptides, the four self-reported headline figures, the n=38 twelve-week study footnote naming Corneometer, Moisturemeter EpiD, Cutometer and Antera 3D, the chest/legs/arms/hands/knees site list, and the absence of absorption, side-effect, contra-indication, pregnancy and breast cancer content. Read 28 July 2026.
- S-02Alloy — M4 Face Cream Rx product page The companion product reviewed at R-28, used for the Fig. 1 comparison and as the source of the line's absorption claim, which this page does not repeat.
- S-03Schmidt et al. — Treatment of skin ageing with topical estrogens (Int J Dermatol, 1996) 0.3% estriol applied to facial skin in 59 women over six months, with monthly serum FSH, prolactin and estradiol measurement showing no significant change — the facial evidence base this body product inherits without discussion.
- S-04When applied to facial skin, does estrogen ointment have systemic effects? (PubMed) The systemic-effect question examined for facial application specifically, which is the limitation on extrapolating to chest, arms and legs.
- S-05NASEM — The Clinical Utility of Compounded Bioidentical Hormone Therapy Confirms no FDA-approved estriol product exists in the United States, so this preparation is compounded — a status the page does not state.
- S-06ACOG — Compounded Bioidentical Menopausal Hormone Therapy (Clinical Consensus, 2023) The cautionary position on compounded bioidentical hormones from one of the two bodies Alloy states its physicians follow.